ACIU - long - upcoming catalysts - RISKY!AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurod
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.536 EUR
−55.85 M EUR
29.95 M EUR
61.45 M
About AC Immune SA
Sector
Industry
CEO
Andrea Pfeifer
Website
Headquarters
Lausanne
Founded
2003
ISIN
CH0329023102
FIGI
BBG00DY40R96
AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.
Consololidating a ready to popAnother opportunity from barchart.com. This stock is very volatile so use limit orders to take profit but wait for the weekly candle to close out for stop loss. Price has been consolidating for 6 weeks already. It may take a couple of more weeks nor not, but looks very explosive.
$ACIU is gonna fall todayPupm&Dump trading strategy idea.
$ACIU is rising too much today.
The demand for shares of the company looks lower than the supply.
This and other conditions can cause a fall in the share price today.
So I opened a short position from $11,85;
stop-loss — $12,77;
take-profit — $10,02/MOC
Do not v
$ACIU Ac Immune On Breakout Watchlist
ACIU had the potential for a move into the gap this week.
RSi crossing Mid-point
MACD crossing Zero-line
Momentum Above Zero-line
20 & 7 ma's rising and crossing 50ma.
Alert set for potential entry above $5.75
Targets $6.30 = 100ma
$6.50 = Major Pivot
$6.87 = Monthly candle resistance
$7.45 =
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange AC IMMUNE SA SF-,02 stocks are traded under the ticker IMR.
We've gathered analysts' opinions on AC IMMUNE SA SF-,02 future price: according to them, IMR price has a max estimate of 10.52 EUR and a min estimate of 7.10 EUR. Watch IMR chart and read a more detailed AC IMMUNE SA SF-,02 stock forecast: see what analysts think of AC IMMUNE SA SF-,02 and suggest that you do with its stocks.
Yes, you can track AC IMMUNE SA SF-,02 financials in yearly and quarterly reports right on TradingView.
AC IMMUNE SA SF-,02 is going to release the next earnings report on Aug 6, 2025. Keep track of upcoming events with our Earnings Calendar.
IMR earnings for the last quarter are −0.20 EUR per share, whereas the estimation was −0.21 EUR resulting in a 7.18% surprise. The estimated earnings for the next quarter are −0.19 EUR per share. See more details about AC IMMUNE SA SF-,02 earnings.
AC IMMUNE SA SF-,02 revenue for the last quarter amounts to 1.03 M EUR, despite the estimated figure of 350.52 K EUR. In the next quarter, revenue is expected to reach 2.12 M EUR.
IMR net income for the last quarter is −19.57 M EUR, while the quarter before that showed −17.39 M EUR of net income which accounts for −12.50% change. Track more AC IMMUNE SA SF-,02 financial stats to get the full picture.
No, IMR doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 6, 2025, the company has 172 employees. See our rating of the largest employees — is AC IMMUNE SA SF-,02 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AC IMMUNE SA SF-,02 EBITDA is −50.96 M EUR, and current EBITDA margin is −184.40%. See more stats in AC IMMUNE SA SF-,02 financial statements.
Like other stocks, IMR shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AC IMMUNE SA SF-,02 stock right from TradingView charts — choose your broker and connect to your account.